Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa
- Conditions
- Glycogen Storage Disease Type IA
- Registration Number
- NCT04708015
- Lead Sponsor
- Ultragenyx Pharmaceutical Inc
- Brief Summary
The primary objective of this study is to assess the percentage of time patients were in normal glucose control.
- Detailed Description
Retrospective Dexcom G6 iCGM data stored in the Clarity cloud from eligible patients will be accessed and downloaded, stripped of patient-identifying information and provided to the contract research organization (CRO) to review prior to sending to the Sponsor for analysis of glycemic control. The CRO will ensure data shared with the Sponsor is de-identified and transferred over a secure file transfer platform. Further, Remote Site Specialists (RSSs) from the CRO will work with the healthcare providers (HCPs) from participating sites to obtain additional patient data including medical history, prescribed diet, cornstarch/Glycosade use and demographic data directly, if available, from the medical charts and will enter this information into an electronic data capture (EDC) system.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Diagnosis of GSDIa confirmed by either liver biopsy or molecular testing.
- Currently using the Dexcom G6 iCGM for glycemic control and with approximately one (1) month of CGM data available on the Dexcom Clarity cloud and have authorized sharing of data with thereferral center through the Dexcom Clarity app.
- Presence or history of any disease, condition or chronic medication that, in the Investigator's opinion, would significantly affect interpretation of study results.
- Use of any investigational product or investigational medical device within 30 calendar days preceding screening or before completion of all scheduled study assessments during study enrollment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of time spent in normal glucose control (defined as glucose levels between 70 mg/dL - 120 mg/dL) over a seven-day period 7 days
- Secondary Outcome Measures
Name Time Method Percentage of time where low glucose values were (< 70mg/dL) over a seven-day period 7 days Total number of low glycemic events (< 70 mg/dL) over a seven-day period 7 days
Trial Locations
- Locations (2)
UT Health - McGovern Medical School
🇺🇸Houston, Texas, United States
University Medical Center Groningen
🇳🇱Groningen, Netherlands